Article · Wikipedia archive · Last revised Jun 14, 2026

Precigen

Precigen, Inc. is an American biotechnology company. Its president and CEO is Helen Sabzevari.

Last revised
Jun 14, 2026
Read time
≈ 1 min
Length
307 w
Citations
10
Source
Wikipedia ↗
Precigen, Inc.
Nasdaq: PGEN
Russell 2000 Component
IndustryBiotechnology
FoundedMay 21, 1998 (1998-05-21)
Headquarters
Germantown, Maryland
,
US
RevenueIncrease $91 million (2019)1
Number of employees
600
Websiteprecigen.com

Precigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari.

Intrexon was founded in 1998, and is headquartered in Germantown, Maryland.23 With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells.4

History

In 2015, Intrexon purchased Oxitec, a maker of genetically sterile insects, for $160 million.5 In April 2019, Intrexon formed a subsidiary called Precigen, with a focus on human gene therapy. Precigen went on to win orphan drug status from the FDA for a CAR-T based therapy (investigational drug name PRGN-3006) to treat acute myeloid leukemia.67 In early 2020, Intrexon adopted the name of its subsidiary, Precigen, and narrowed its focus to human gene editing.89 With the change in name the CEO of subsidiary Precigen, Helen Sabzevari, took over leadership of the company from Randal J. Kirk.7

See also

See also

References

References

  1. "Precigen Revenue 2012-2021 | PGEN".
  2. "Intrexon Corporation: Private Company Information". Bloomberg. Retrieved 2017-06-26.
  3. "Intrexon Corp (XON) Company Profile". Reuters.com. Retrieved 2017-06-26.
  4. "FAQ | Intrexon". Intrexon InvestorRoom. Retrieved 2018-03-28.
  5. Nickel, Rod (15 September 2015). "Market turbulence or not, North American investors plow into farm tech". Reuters. Retrieved 9 October 2015.
  6. "PRGN-3006 Adoptive Cellular Therapy Relapsed or Refractory AML or High Risk MDS". FDA. Retrieved 6 April 2020.
  7. Gilgore, Sara (6 January 2020). "Intrexon will take the name of its subsidiary. That company just scored orphan status for a rare cancer drug". American City Business Journals. Retrieved 6 April 2020.
  8. "INTREXON CORPORATION IS NOW PRECIGEN, INC". Precigen. Retrieved 6 April 2020.
  9. Helmstetter, Michael (30 March 2020). "The Promise And Fear Of Gene Editing". Forbes. Retrieved 6 April 2020.
External links

Official website